By Owen Davis “One of the weird facts about executive compensation is that the numbers companies give to the SEC don’t really line up with how much cash executives actually take home. In 2014, for instance, the top 500 highest-paid…
AIR IMPACT
Recognition of AIR research, opinions, and people in the media and elsewhere
Recession on the horizon
By Martin Hart-Landsberg “According to Bloomberg News, analysts at a number of major financial institutions see “mounting evidence” that a recession is not too far away.”… [Click HERE to read the full article]
Low rates benefited investors more than ordinary Americans
By Rana Foroohar “One of the great ironies of the 10 years following the financial crisis is the way in which low interest rate monetary policy — which was designed to get Main Street USA back up and running and…
Economist seeks to debunk ‘shareholder value’
By David M. Katz “Using strong language in a recent working paper, an economist has set his sights on debunking two of the most well-established ideas in corporate finance: the notion that “maximizing shareholder value” should be a company’s main goal…
Even after nuclear catastrophe, SCANA execs eye bonuses
By Steve Bailey “So with consumers yelling for heads to roll, what is South Carolina Electric & Gas planning next? The largest stock buyback in the company’s history, which will help shareholders and bolster executive bonuses.”… [Click HERE to read…
Steve Bannon will crash our economy if no one stops him
By Linette Lopez “Left to his own devices, Steve Bannon will crash our economy. In an interview with The American Prospect, the White House chief strategist laid out a single specific goal for American “economic nationalism” in the Trump administration: a…
Les pharmas dépensent autant pour leurs actionnaires que pour la recherché
By Marie Maurisse “Entre 2006 et 2015, Novartis a versé presque autant d’argent à ses actionnaires qu’elle n’en a investi en recherche et développement (R&D). Une étude récente pointe les dérives d’une telle évolution.”… [Click HERE to read the full article]
Economist argues maximizing shareholder value hurts drug innovation
By Daniel Levine “The pharmaceutical industry has long argued that high drug prices are necessary to incentivize investment in and fund high-risk research and development of innovative new therapies.”… [Click HERE to listen the interview]
How stock buybacks cause economic stagnation
By Arne Alsin “Corporate suicide.” That’s how two researchers, Robert Ayres and Michael Olenick, are now describing the stock buyback boom in the U.S. economy. For the uninitiated, buybacks are the process by which a corporation buys up its own…
Don’t pop open the bubbly just yet! This market buying activity used to be illegal
By Richard Bowen “The stock market is up and we should all be celebrating. However before you pop open the champagne, let’s look at the real story. The stock buybacks driving the market used to be illegal because they manipulated…
